1 0 0 0 OA ADAMTS13物語

著者
副島 見事 小亀 浩市 松本 雅則
出版者
一般社団法人 日本血栓止血学会
雑誌
日本血栓止血学会誌 (ISSN:09157441)
巻号頁・発行日
vol.20, no.4, pp.377-397, 2009 (Released:2009-08-20)
参考文献数
86
被引用文献数
1 1
著者
原田 直明 岡嶋 研二
出版者
一般社団法人 日本血栓止血学会
雑誌
日本血栓止血学会誌 (ISSN:09157441)
巻号頁・発行日
vol.21, no.6, pp.616-618, 2010 (Released:2010-12-20)
参考文献数
7

この論文は撤回されました。
著者
山下 勉 香西 かおり 井上 典子 三村 幸一 松岡 瑛
出版者
The Japanese Society on Thrombosis and Hemostasis
雑誌
日本血栓止血学会誌 (ISSN:09157441)
巻号頁・発行日
vol.3, no.1, pp.49-56, 1992
被引用文献数
2

We have investigated the use of synthetic thrombin inhibitors in assays of thrombin-antithrombin III complexes (TAT). In a purified system, when antithrombin III (AT-III) was incubated with thrombin, a complex of 90KD was formed gradually during the first 60 minutes and this complex was converted to lower molecular weight species (78-86×10<sup>3</sup>) within 48 hours. Additionally, the interaction of thrombin and AT-III was studied in the presence of heparin. A 93KD complex was formed immediately and then lower molecular weight complexes (78-86×10<sup>3</sup>) were formed during 60 minutes of incubation. In these circumstances, therefore, heparin seemed to accelerate the breakdown of TAT complexes. Plasma values of TAT were measured by ELISA in the presence of heparin and were reduced by approximately 55per cent during 48 hours of incubation. These findings suggested that the biochemical nature of TAT was modified during incubation, and that the assays for TAT in plasma might not detect lower molecular weight forms of the complex. However, a synthetic thrombin inhibitor, argatroban (0.1mM/<i>l</i>) prevented these changes. The levels of TAT in plasma were increased by adding tissue factor or contact factor activator to the assay mixture. Argatroban (0.01mM/<i>l</i>) or another synthetic protease inhibitor, FOY (4.3mM/<i>l</i>), inhibited this generation of TAT. These observations suggested that argatroban minimized the changes of TAT molecular weight and prevented generation of TAT <i>in vitro</i>. The data indicated that the addition of argatroban (final concentration 0.1mM/<i>l</i>) to plasma would permit more accurate measurements of circulating levels of TAT.
出版者
一般社団法人 日本血栓止血学会
雑誌
日本血栓止血学会誌 (ISSN:09157441)
巻号頁・発行日
vol.25, no.5, pp.629-646, 2014 (Released:2014-10-25)
参考文献数
104
被引用文献数
5 8
著者
榛沢 和彦
出版者
一般社団法人 日本血栓止血学会
雑誌
日本血栓止血学会誌 (ISSN:09157441)
巻号頁・発行日
vol.19, no.1, pp.39-44, 2008 (Released:2008-03-25)
参考文献数
13
被引用文献数
2

Point1)深部静脈血栓症(DVT),特にヒラメ筋静脈血栓は日本人でも多い.2)DVT検査法のゴールドスタンダードは下肢静エコーと造影CTである.3)大腿静脈は臥位で,下腿静脈は座位でエコー検査する.4)静脈血栓の診断は血栓陰影の有無と圧迫法で確認する.5)ヒラメ筋静脈血栓は非生理的状態で急速進展し肺塞栓症の原因になる.6)器質化したDVTは慢性反復性となり非生理的状態で肺塞栓症の原因になる.